Share

In This Article

  1. What Kisspeptin Actually Is
  2. What The Human Research Shows
  3. What About Men?
  4. Why This Matters Beyond Fertility Clinics
  5. The Honest Bottom Line

What Kisspeptin Actually Is

Kisspeptin is a peptide hormone produced in your hypothalamus - the part of your brain that controls hormones, appetite, temperature, and sleep. It was originally discovered in 1996 as a tumour suppressor gene (called KiSS-1, named after Hershey's Kisses because the lab was in Hershey, Pennsylvania). It wasn't until 2003 that scientists realised it plays the central role in controlling human reproduction.

Kisspeptin's job is to activate GnRH (gonadotropin-releasing hormone) neurons in your hypothalamus. GnRH then triggers the release of LH (luteinising hormone) and FSH (follicle-stimulating hormone) from your pituitary gland. These hormones control everything: puberty, menstrual cycles, ovulation, testosterone production, sperm development. Kisspeptin sits at the very top of this cascade. It's the master switch.

Strong - Multiple Human Clinical Trials

What It Does In Your Body

What The Human Research Shows

Kisspeptin has more clinical trial evidence than most peptides in the reproductive space. The research is centred at Imperial College London, led by Professor Waljit Dhillo's team.

IVF - A Safer Ovulation Trigger

Standard IVF uses hCG (human chorionic gonadotropin) to trigger the final maturation of eggs before collection. The problem: hCG can cause ovarian hyperstimulation syndrome (OHSS) - a potentially dangerous condition where the ovaries swell, fluid leaks into the abdomen, and in severe cases, blood clots can form.

Kisspeptin-54 triggers ovulation through a different pathway - it produces a more natural LH surge that closely mimics what happens in a normal menstrual cycle. Clinical trials published in the Journal of Clinical Investigation showed kisspeptin-54 successfully triggered egg maturation in IVF patients with zero cases of OHSS. Pregnancy rates ranged from 23-37% across randomised trials.

MVT-602 - The Next-Generation Version (2024)

MVT-602 is a kisspeptin analogue designed to last longer in the body. In 2024, two randomised clinical trials in healthy premenopausal women showed that MVT-602 at an intermediate dose produced an LH surge that closely resembles the natural mid-cycle surge - more accurately than any current trigger agent. This triphasic pattern is considered ideal for IVF because it mimics what the body does naturally.

Intranasal Delivery (2025)

A landmark 2025 study published in eBioMedicine (The Lancet family) showed that intranasal kisspeptin-54 - a nasal spray - rapidly stimulated gonadotropin release in both healthy men and women, and in patients with hypothalamic amenorrhoea. No side effects or adverse events. This is significant because it opens the door to a non-injection route of administration, which would be far more practical for clinical use.

Hypothalamic Amenorrhoea

Women who lose their periods due to stress, weight loss, or excessive exercise have suppressed kisspeptin signalling. Studies show that kisspeptin administration can restore LH pulsatility in these patients, potentially restarting menstrual cycles without the need for hormone replacement therapy.

What About Men?

Kisspeptin also affects male reproductive function:

Why This Matters Beyond Fertility Clinics

Kisspeptin's role as the link between metabolic health and reproductive function has broader implications:

The Honest Bottom Line

Kisspeptin is a genuinely exciting peptide with strong clinical evidence. Unlike most peptides discussed in health optimisation, it has multiple proper human clinical trials, a clear mechanism, and real clinical applications in IVF and reproductive medicine. The 2025 intranasal delivery breakthrough could make it far more accessible. For fertility applications, the evidence is strong and growing. For broader hormonal and anti-ageing applications, the science is promising but earlier-stage. This is one to watch - it's being developed through proper pharmaceutical channels with serious clinical trial programmes.

For the full peptide landscape, read the Complete Peptide Guide.

This article is for educational purposes only. It is not medical advice. Peptides discussed here may not be approved for human use in your country. Always consult a qualified medical professional before making any health decisions.